

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Currently Amended) A compound of the formula  
N-1-[(4-chlorophenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)phenyl]-  
-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,  
N-1-[(4-ethynylphenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)-  
phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,  
N-1-[(4-chlorophenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-  
phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,  
N-1-[(4-ethynylphenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}-  
phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,  
N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-  
phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

or pharmaceutically usable derivatives, salts or stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I



in which

R denotes Hal,  $-C\equiv C-H$ ,  $-C\equiv C-A$  or OA,


$R^1$  denotes H,  $=O$ , Hal, A, OH, OA, A-COO-, Ph-(CH<sub>2</sub>)<sub>n</sub>-COO-, cycloalkyl-(CH<sub>2</sub>)<sub>n</sub>-COO-, A-CONH-, A-CONA-, Ph-CONA-, N<sub>3</sub>, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOH, COOA, CONH<sub>2</sub>, CONHA, CON(A)<sub>2</sub>, O-allyl, O-propargyl, O-benzyl,  $=N-OH$ ,  $=N-OA$  or  $=CF_2$ ,

$R^2$  denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

$R^3$  denotes H, Hal or A,

$R^4$  denotes  $-C_6H_4-(CH_2)_n-NR^5R^{5'}$ ,  $-C(=NR^5)NR^5R^{5'}$ ,



$R^5$ ,  $R^{5'}$  each, independently of one another, denote H or A,

A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,


Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,


or pharmaceutically usable derivatives, salts and stereoisomers thereof, comprising

reacting

a) a compound of the formula II




with a chloroformate derivative to give an intermediate carbamate derivative,  
subsequently reacting said intermediate with a compound of the formula III



or


b) reacting a compound of the formula III

with a compound of the formula IV




or

c) reacting a compound of the formula V



with a compound of the formula VI



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group

and/or converting

a base or acid of the formula I into one of its salts.

10. (Cancelled)

11. (Cancelled).

12. (Currently Amended) A pharmaceutical composition comprising at least one compound according to Claim 8 and/or pharmaceutically usable derivatives, salts and stereoisomers thereof, including mixtures thereof in all ratios, and pharmaceutically acceptable excipients and/or adjuvants.
13. (Cancelled).
14. (Previously Presented) A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 8 and/or pharmaceutically useable derivatives, salts or stereoisomers thereof.
15. (Cancelled)
16. (Cancelled).
17. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.
18. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-{[4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.
19. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-{[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

20. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

21. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

22. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

23. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

24. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

25. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

26. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

27. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

28. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

29. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

30. (New): A compound according to claim 8, wherein said compound is N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

31. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.

32. (New): A compound according to claim 8, wherein said compound is N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, or a pharmaceutically usable salt thereof.